Bambusa Therapeutics Doses First Patient With BBT002 in Phase Ib COPD Trial

Bambusa Therapeutics Doses First Patient With BBT002 in Phase Ib COPD Trial

By, Admin 7 January 2026

Bambusa Therapeutics has reached a key clinical milestone. The company has dosed the first patient in its Phase Ib trial of BBT002.

What Is BBT002?

BBT002 is a bispecific antibody designed to target two core drivers of type 2 inflammation:

  • IL-4Rα (IL-4 / IL-13 signaling)
  • IL-5

Both pathways shape allergic and inflammatory disease across the human lifespan. Instead of treating symptoms in isolation, BBT002 aims to suppress the shared biology behind multiple diseases.

Trial Overview

The Phase Ib study will evaluate BBT002 in:

  • Chronic obstructive pulmonary disease (COPD)
  • Asthma
  • Chronic rhinosinusitis with nasal polyps (CRSwNP)

Key endpoints include:

  • Safety and tolerability
  • Pharmacokinetics (PK)
  • Pharmacodynamics (PD)

Initial data are expected in H2 2026.

Why COPD Matters?

COPD remains one of the most underserved respiratory diseases.

Despite its scale:

  • Therapeutic innovation has been limited
  • Disease-modifying options are scarce

Type 2 inflammation is increasingly recognized as a key driver in a subset of COPD patients. BBT002 is designed to address that biology directly.

A “Platform-in-a-Molecule” Strategy

Type 2 inflammation evolves over time. It often begins early and progresses across organs:

  • Atopic dermatitis and food allergy in childhood
  • Asthma and CRSwNP in adulthood
  • COPD later in life

BBT002 targets this continuum with a single, long-acting molecule. The goal: broader, deeper, and more durable disease control.

Leadership Perspective

“COPD has seen remarkably limited therapeutic innovation,” said Dr. Shanshan Xu, Founder and CEO.

Moving BBT002 from healthy volunteers to proof-of-concept studies in seven months reflects:

  • Platform strength
  • Execution speed
  • Scientific discipline

What’s Next for Bambusa?

Bambusa is entering 2026 with momentum. The company expects:

  • Up to 10 clinical readouts
  • Five proof-of-concept studies across programs

Multiple assets are advancing in parallel.

Bambusa’s Growing Pipeline

Key programs include:

  • BBT001: IL-4Rα × IL-31 bispecific for atopic dermatitis
  • BBT002: IL-4Rα × IL-5 bispecific for type 2 inflammatory diseases
  • BBT003 & BBT004: Preclinical programs in gastroenterology and rheumatology

All are powered by Bambusa’s antibody engineering platform, built for:

  • Half-life extension
  • High-concentration subcutaneous delivery

Bottom Line

BBT002 represents a shift from single-disease targeting to biology-first therapeutics.

If successful, it could redefine how type 2 inflammatory diseases are treated—across organs, ages, and disease stages.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!